COSCIENS Biopharma Inc. (CSCI:TSX) closed at $8.32 on November 13, 2026, down 2.35% on the day. The stock trades 79.0% below its 52-week high of $39.60 and 18.9% above its 52-week low of $7.00. Over the past year, it lost 68.7%. COSCIENS Biopharma Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, CSCI closed higher on 103 days (41%). Its best day was April 6, 2026 (+53.95%) and its worst was July 3, 2026 (-65.04%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 8 times.
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
Find more stocks like CSCI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.